Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from ...

Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed ...

CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone, a Phase ...

Mizuho (NYSE:MFG) analysts maintained their Neutral rating on Relmada Therapeutics Inc (NASDAQ:RLMD), with a steady price target of $1.00, following the announcement of a new acquisition. The stock, ...

In a challenging year for Relmada Therapeutics (NASDAQ:RLMD), the company's stock has plummeted to a 52-week low, trading at just $0.34. According to InvestingPro data, the... Relmada Therapeutics ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investing.com - Relmada Therapeutics (NASDAQ: RLMD) reported third quarter EPS of $-0.73, $0.18 better than the analyst estimate of $-0.91. Revenue for the quarter came in at... ByInvesting.com ...

Relmada Therapeutics, Inc. (RLMD) stock price is 0.34 and Relmada Therapeutics, Inc. (RLMD) 10-day simple moving average is 0.37. Relmada Therapeutics, Inc. (RLMD) stock price is 0.34 and Relmada ...